Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts (3)
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...
Reuters6d
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Patients on the once-weekly 7.2 milligram dose of Novo's drug for 72 weeks lowered their weight by 20.7% during the trial, compared with 17.5% for the 2.4 milligram dose and 2.4% for the placebo.